Coverage
-
March 21, 2023
GW Pharmaceuticals investors urged a California federal judge on Monday to grant preliminary approval to a $7.75 million settlement that ends their claims the British company misled shareholders to push through its $7.2 billion sale to Ireland-based Jazz Pharmaceuticals, calling it an "excellent" result.
3 other articles on this case.
View all »